Prediction of donor related lung injury in clinical lung transplantation using a validated ex vivo lung perfusion inflammation score

Andrew T Sage Melissa Richard-Greenblatt Kathleen Zhong Xiao Hui Bai Matthew B Snow Monica BabitsAadil Ali Cristina Baciu Jonathan C Yeung Mingyao Liu Marcelo Cypel Kevin C Kain Shaf Keshavjee J Heart Lung Transplant . 2021 Mar 5;S1053-2498(21)02219-1. doi: 10.1016/j.healun.2021.03.002. Online ahead of print. PMID: 33781664 DOI:

Ex vivo lung perfusion (EVLP) is an isolated organ assessment technique that has revolutionized the field of lung transplantation and enabled a safe increase in the number of organs transplanted. The objective of this study was to develop a protein-based assay that would provide a precision medicine approach to lung injury assessment during EVLP.

Perfusate samples collected from clinical EVLP cases performed from 2009 to 2019 were separated into development (n = 281) and validation (n = 57) sets to derive and validate an inflammation score based on IL-6 and IL-8 protein levels in perfusate. The ability of improve accuracy of EVLP decision-making. Inflammation scores were compared to conventional clinical EVLP assessment parameters and associated with outcomes, including primary graft dysfunction and patient care in the ICU.

An inflammation score accurately predicted the decision to transplant (AUROC 68% [95% CI 62-74]) at the end of EVLP and those transplants associated with short ventilator times (AUROC 73% [95% CI 66-80]). The score identified lungs more likely to develop primary graft dysfunction at 72-hours post-transplant (OR 4.0, p = 0.03). A model comprised of the inflammation score and ∆PO2 was able to determine EVLP transplants that were likely to have excellent recipient outcomes, with an accuracy of 87% [95% CI 83-92].

The adoption of an inflammation score will improve accuracy of EVLP decision-making and increase confidence of surgical teams to determine lungs that are suitable for transplantation, thereby improving organ utilization rates and patient outcomes.

cytokines; ex vivo lung perfusion; personalized medicine; post-transplant outcomes; predictive biomarkers.

Copyright © 2021. Published by Elsevier Inc.